Diabetes Care, Vol 23, Issue 2 202-207, Copyright © 2000 by American Diabetes Association

ARTICLES

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia

M Hanefeld, KP Bouter, S Dickinson and C Guitard
Outpatient Department, Institute of Clinical Metabolic Research, Medical Faculty, Technical University of Dresden, Germany.

OBJECTIVE: The objective of the study was to assess the efficacy and safety of four fixed doses of nateglinide compared with placebo in the treatment of patients with type 2 diabetes with focus on the prandial state. RESEARCH DESIGN AND METHODS: This randomized double-blind placebo-controlled multicenter study was conducted in 289 patients who received either nateglinide at doses of 30 mg (n = 51), 60 mg (n = 58), 120 mg (n = 63), or 180 mg (n = 57) or placebo (n = 60) before three main meals for 12 weeks. Levels of HbA1c, fasting plasma glucose (FPG), fructosamine, and plasma lipids were measured at predetermined intervals, and the effects of nateglinide on prandial glucose insulin, C-peptide, and triglyceride levels were measured after a liquid standard meal (Sustacal; Mead Johnson, Evansville, IN). Adverse events and hypoglycemic episodes were recorded. RESULTS: After a liquid meal challenge, nateglinide rapidly increased mealtime insulin levels within 30 min of drug intake and reduced mealtime glucose excursions without affecting triglyceride levels. At study end point, reduction of HbA1c levels was statistically significantly greater with nateglinide at doses of 60, 120, and 180 mg than placebo (-0.45, -0.62, and -0.64%, respectively; P<0.05). The mean level of FPG was significantly reduced versus placebo in the nateglinide 120-mg group only (-1.14 mmol/l P<0.01). Overall, nateglinide was well tolerated. CONCLUSIONS: This study demonstrated that nateglinide improves mealtime and mean glycemic control in a dose-dependent manner by restoring early insulin secretion phase. Nateglinide was well tolerated and is suitable for the treatment of patients with type 2 diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Selvin, S. Bolen, H.-C. Yeh, C. Wiley, L. M. Wilson, S. S. Marinopoulos, L. Feldman, J. Vassy, R. Wilson, E. B. Bass, et al. Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review Arch Intern Med, October 27, 2008; 168(19): 2070 - 2080. [Abstract] [Full Text] [PDF]

				D. F. Kruger Exploring the Pharmacotherapeutic Options for Treating Type 2 Diabetes The Diabetes Educator, May 1, 2008; 34(Supplement_3): 60S - 65S. [Abstract] [Full Text] [PDF]

				B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]

				A. Y.Y. Cheng and I. G. Fantus Oral antihyperglycemic therapy for type 2 diabetes mellitus Can. Med. Assoc. J., January 18, 2005; 172(2): 213 - 226. [Abstract] [Full Text] [PDF]

				J. Rosenstock, D. R. Hassman, R. D. Madder, S. A. Brazinsky, J. Farrell, N. Khutoryansky, and P. M. Hale Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study Diabetes Care, June 1, 2004; 27(6): 1265 - 1270. [Abstract] [Full Text] [PDF]

				A. Sevinc Should Diabetic Patients Treated Long-term With Sulfonylureas Be Switched to Nateglinide? Arch Intern Med, July 28, 2003; 163(14): 1741 - 1741. [Full Text] [PDF]

				{blacktriangledown}Nateglinide and {blacktriangledown}repaglinide for type 2 diabetes? DTB, July 1, 2003; 41(7): 52 - 54. [Abstract] [Full Text] [PDF]

				S. Del Prato, R. J. Heine, L. Keilson, C. Guitard, S. G. Shen, and R. P. Emmons Treatment of Patients Over 64 Years of Age With Type 2 Diabetes: Experience from nateglinide pooled database retrospective analysis Diabetes Care, July 1, 2003; 26(7): 2075 - 2080. [Abstract] [Full Text] [PDF]

				R.M. Califf Insulin resistance: a global epidemic in need of effective therapies Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C13 - C18. [Abstract] [PDF]

				D. Devineni, Y. H. Walter, H. T. Smith, J. S. Lee, P. Prasad, and J. F. McLeod Pharmacokinetics of Nateglinide in Renally Impaired Diabetic Patients J. Clin. Pharmacol., February 1, 2003; 43(2): 163 - 170. [Abstract] [Full Text]

				M. F. Carroll, A. Izard, K. Riboni, M. R. Burge, and D. S. Schade Control of Postprandial Hyperglycemia: Optimal use of short-acting insulin secretagogues Diabetes Care, December 1, 2002; 25(12): 2147 - 2152. [Abstract] [Full Text] [PDF]

				C. Saloranta, K. Hershon, M. Ball, S. Dickinson, and D. Holmes Efficacy and Safety of Nateglinide in Type 2 Diabetic Patients with Modest Fasting Hyperglycemia J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4171 - 4176. [Abstract] [Full Text] [PDF]

				J. Rosenstock, S. G. Shen, M. R. Gatlin, and J. E. Foley Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes Diabetes Care, September 1, 2002; 25(9): 1529 - 1533. [Abstract] [Full Text] [PDF]

				L. S. Cozma, S. D. Luzio, G. J. Dunseath, K. W. Langendorg, T. Pieber, and D. R. Owens Comparison of the Effects of Three Insulinotropic Drugs on Plasma Insulin Levels After a Standard Meal Diabetes Care, August 1, 2002; 25(8): 1271 - 1276. [Abstract] [Full Text] [PDF]

				A. Schweizer, M. Ball, D. R Owens, F. Cressier, D. O Holmes, and P. Brunel Comparison of the postprandial glucose and insulin profiles with nateglinide and gliclazide in type 2 diabetic patients The British Journal of Diabetes & Vascular Disease, May 1, 2002; 2(3): 228 - 232. [Abstract] [PDF]

				S. E. Inzucchi Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review JAMA, January 16, 2002; 287(3): 360 - 372. [Abstract] [Full Text] [PDF]

				Managing Type 2 Diabetes in the Elderly The Diabetes Educator, January 1, 2002; 28(1_suppl): 3 - 11. [PDF]

				P. A. Hollander, S. L. Schwartz, M. R. Gatlin, S. J. Haas, H. Zheng, J. E. Foley, and B. E. Dunning Importance of Early Insulin Secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes Diabetes Care, June 1, 2001; 24(6): 983 - 988. [Abstract] [Full Text]

				M. L. Weaver, B. A. Orwig, L. C. Rodriguez, E. D. Graham, J. A. Chin, M. J. Shapiro, J. F. McLeod, and J. B. Mangold Pharmacokinetics and Metabolism of Nateglinide in Humans Drug Metab. Dispos., April 1, 2001; 29(4): 415 - 421. [Abstract] [Full Text]

				R. G. Moses, R. Gomis, K. B. Frandsen, J.-L. Schlienger, and I. Dedov Flexible Meal-Related Dosing With Repaglinide Facilitates Glycemic Control in Therapy-Naive Type 2 Diabetes Diabetes Care, January 1, 2001; 24(1): 11 - 15. [Abstract] [Full Text]

				J. B. Kalbag, Y. H. Walter, J. R. Nedelman, and J. F. McLeod Mealtime Glucose Regulation With Nateglinide in Healthy Volunteers: Comparison with repaglinide and placebo Diabetes Care, January 1, 2001; 24(1): 73 - 77. [Abstract] [Full Text]